SIR -It was recently suggested in this journal that the 1988-89 peak in the birth prevalence of neural tube defects (NTD) in eastern Turkey was due to the Chernobyl disaster.' Two other reports from the western hemisphere have described dramatic increases in the birth prevalence of NTD. In Jamaica the increase in several types of NTD between July 1989 and March 1990 was suggested to be attributable to a post-hurricane scarcity.2 In Texas a 1989 increase in anencephaly was felt to be a problem of exposure to dumped inorganic solvents or to be due to a high proportion of Hispanic people, known to have an increased incidence.3
It is difficult to assess the importance of this undefined increase in NTD births. It has occurred two years later than the three studies cited above, thereby suggesting yet another unknown causative environmental factor. It may be possible to explain the phenomenon by a normal clustering of space-time events. In high risk areas it is difficult to assess the impact of an unknown environmental factor acting against a background of genetic predisposition. It is more unlikely that there has been a change in the nutritional status of the population. Nevertheless, in view of current thought that NTD can be prevented by vitamin supplementation,' this fact must be kept in mind when discussing changing trends. ' Steps have now been taken to establish a prospective registry of planned or continuing randomised controlled trials in the area of smoking cessation.
A number of researchers with experience in the area of intervention for smoking cessation have recently been approached to obtain information about trials of smoking cessation interventions currently in progress.
The initial response has been encouraging, but it is possible that some people who are working in this field and ought to be approached have been inadvertently missed.
We are therefore seeking the help of all researchers to ensure that a registration form is completed by the principal investigator for all randomised controlled trials of a smoking cessation intervention of which they may be aware, and which is currently in progress or substantially advanced in the planning stages. To be eligible for inclusion in the registry, a trial must (a) be unpublished, (b) include at least two groups, (c) allocation to the groups must be by either a random or quasi-random method, (eg alternation, year of birth, etc), and (d) the trial must be related to an aspect of smoking cessation. Trials examining abstinence rates, relapse prevention, withdrawal symptoms, training or encouraging health professionals in smoking cessation techniques, or any aspect of smoking cessation research are all eligible for inclusion. If you are in doubt as to whether a trial is suitable for inclusion, we suggest you still complete a registration form.
Once the register has been assembled a copy will be distributed to all contributors and it will be published in summary form on an annual or bi-annual basis.
The registry will not collect any trial result data or participant information, although the existence of such a register may facilitate efforts to establish collaborative groups who wish to undertake more detailed systematic reviews in the future, similar to those undertaken in other fields.
Trial registration forms are available on request from:
The 
